Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Osteoporosis

• Clinical Controlled Study on the Efficacy of Denosumab in Treating Osteoporosis in the Domestic Population and Its Impact on Sarcopenia-related Outcomes
• Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With Osteoporosis
• Preserving Geriatric Muscle With an Osteoporosis Medication
• A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.
• The Optimised Use of Romozosumab Study
• Effect of Acetylcholinesterase Inhibitors on Bone Metabolism
• Senolytics to Improve Osteoporosis Therapy
• EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy
• Rhythmic Estradiol and Bone Health
• Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis
• Comparison of Efficacy of Denosumab With Eldecalcitol or Native Vitamin D in Postmenopausal Women With Osteoporosis.
• A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis
• Muscle Impact of Treating Osteoporosis
• Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2
• Efficacy and Safety of Minodronate in Patients With Low Back Pain
• Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women
• Effect of Laser Acupuncture on Forearm Bone Mineral Density and Wrist Pain in Osteoporotic Postmenopausal Women: A Randomized Controlled Trial
• Single Ascending Dose or 14-day Study With AFA-281 in Healthy Volunteers
• Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease
• Denosumab Biosimilar Injection in Post Menopausal Women With Osteoporosis
• Denosumab Effect on Bone Quality and Function After Lumbar Fusion Surgery
• Effectiveness and Safety of EuBone® Capsules for Bone Health in Postmenopausal Women
• Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis
• Randomized, Double-Blind, Parallel Design, 2-arm,Multicenter Study Assessing the Biosimilarity of AVT03 and US-Prolia® in Postmenopausal Women With Osteoporosis
• TST002 Intervenous Injection in Postmenopausal Women and Men With Reduced Bone Mineral Density
• A Multi Center, Randomized, Open-label, Parallel, Phase IV Clinical Trial to Evaluate Efficacy and Safety of MASI BONE S (Alendronate Sodium Trihydrate) in Postmenopausal Women With Osteoporosis
• Effect of Vitamin D and Denosumab on Bone Remodelling in Women With Postmenopausal Osteoporosis
• The Study of Chinese Medicine for the Treatment of Primary Osteoporosis
• A Clinical Trial to Evaluate Efficacy of Once or Twice ZOledronic Acid After Different Duration of denOsumMab Administration in Postmenopausal Women With Osteoporosis (ZOOM Study)
• Frequency of Hyperparathyroidism in Postmenopausal Osteoporosis and Its Treatment
• Antiresorptive Effect of Treatment With Risedronate and Vitamin D in Postmenopausal Patients
• A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of MB09 [Proposed Denosumab Biosimilar] to Prolia® [EU-sourced] in Postmenopausal Osteoporosis (SIMBA Study)
• MAGnesium Effect With ANtiosteoporotic Drugs
• The Effect of Effervescent Alendronate on Bone Turnover
• A Phase III Clinical Study of Minodronate Tablets in Postmenopausal Women With Osteoporosis
• Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis
• Use of Ibandronate in Diabetic Patients
• A First-in-Human Study Evaluating AGA2118 in Postmenopausal Women
• Efficacy and Safety of MW031 in PMO Subjects
• Effects of Denosumab on Bone Fusion in Osteoporotic Patients After Lumbar Fusion
• Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI
• Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover
• Vitamin D Status and Bone Metabolism Status in Children With Congenital Epidermolysis Bullosa
• Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI
• The Optimal Sequential Therapy After Long Term Denosumab Treatment
• The Optimal Long Term Treatment Strategy of Anti-resorptive Medications---The Extension of Denosumab Sequential Therapy
• Comparative Efficacy and Safety Study of RGB-14-P and Prolia in Women With Postmenopausal Osteoporosis
• A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis
• A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for Fracture
• Romosozumab Use to Build Skeletal Integrity
• Zoledronate Early to Hip Fracture Patients - Safe and Effective?
• Anabolic Therapy in Postmenopausal Osteoporosis
• Effect of GLP-1 Receptor Agonists on Trabecular Bone Score and Visceral Adiposity in Postmenopausal Women With Type 2 Diabetes Mellitus.
• Comparing of the Pharmacokinetic, Safety and Immunogenicity of HS-20090-2 Injection and Prolia® in Healthy Adults
• A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With Osteoporosis
• Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil
• The Effects of Melatonin Treatment on Bone, Marrow, Sleep and Blood Pressure
• Romosozumab/Denosumab Study for Premenopausal IOP
• Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW031 and Prolia® in Healthy Adults
• Clinical Pharmacokinetics and Pharmacodynamics Study of Different Doses of Zoledronic Acid
• Pravastatin Reduces Acute Phase Response of Zoledronic Acid
• Romosozumab in Women With Chronic SCI
• Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis
• Effect of Vitamin K Supplementation on Circulating Levels of Osteocalcin on the Bone Metabolism and Aging
• A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis
• Pearlium®/Effecti-Cal®, a Novel Formulation of Calcium, Vitamin D and Minerals for Prevention of Postmenopausal Bone Loss
• Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Women
• Evaluation of Romosozumab vs. Zoledronic Acid Effect in Patients With Spinal Cord Injury and Low Bone Mineral Density
• Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® .
• Evaluation of Clinical and Bone Density Improvement After Implantation of Allogenic Mesenchymal Stem Cell From Umbilical Cord on Osteoporosis Patients
• Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
• A Multiple Dose Study to Evaluate the Effect of SHR-1222 Injection in Postmenopausal Osteoporosis Patients
• Blackcurrant Modifies Gut Microbiota and Reduces Osteoporosis Risk
• Coral Calcium's Effect on Bone Density in Postmenopausal Women With and Without Ibandronate
• A Study to Evaluate Efficacy and Safety of Denosumab for Prevention and Treatment of Osteoporosis in 1st Time Liver Transplant Recipients.
• Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study
• Alendronate Versus Denosumab in Kidney Transplant Patients
• Abaloparatide Before Total Knee Arthroplasty
• Alterations of GCF Levels of Sclerostin and DKK-1 in Postmenopausal Osteoporosis
• Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture Risk
• Romosozumab Versus Denosumab for Osteoporosis in Long-term Glucocorticoid Users
• Osteoporosis in Primary Hyperparathyroidism
• Study of NaQuinate in Healthy Volunteers
• Treating Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density With Denosumab or Zoledronic Acid
• Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration
• A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass
• Novel Combination Therapy for Osteoporosis in Men
• The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients
• Efficacy of Zoledronic Acid + Colaren vs Zoledronic Acid + Conventional Treatment for Osteoporosis in HIV+ and HIV- Men
• Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers
• Trial of Parkinson's And Zoledronic Acid
• Markers of Osteoporosis in Cystic Fibrosis
• Effects of SHR-1222 on Vascular Inflammatory Factors in Patients With Low Bone Mass
• The PK/PD Study of A Single Subcutaneous Injection of SHR-1222 in Healthy Subjects
• Denosumab Sequential Therapy
• Evaluating the Pharmacokinetic Characteristics of AD-102 in Healthy Volunteers
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women
• Averting Complications of Proton Pump Inhibitor Therapy by Effervescent Calcium Magnesium Citrate
• Breast Cancer Women on Aromatase Inhibitors Treatment
• Preoperative Teriparatide Use on Insertional Torque of Pedicle Screws for Lumbar Fusion Surgery
• Evaluating the Pharmacokinetic Characteristics of AD-101 in Healthy Volunteers
• Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients
• Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption
• Effect of Adrenocorticotropic Hormone on Vascular Endothelial Growth Factor Release in Children Study
• Examination How the Administration Period of Teriparatide Affects Bone Metabolism and Bone Mineral Density Prior to Denosumab Therapy
• Comparative Antiresorptive Efficacy Discontinuation of Denosumab
• Clinical Study on Treatment of Postmenopausal Osteoporosis (Kidney Deficiency and Blood Stasis Syndrome) With Xulin Jiangu Granules
• Vivomixx for Prevention of Bone Loss in Women With Breast Cancer Treated With an Aromatase Inhibitor
• Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)
• A Clinical Trial to Evaluate the Safety and Pharmacokinetic
• MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis
• Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab
• A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis
• Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis
• Bisphosphonates for Prevention of Post-Denosumab Bone Loss
• HDDO-1614 Bio Equivalence Study
• Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Denosumab 60 mg (Arylia) Versus Prolia® in Improvement of Bone Mineral Densitometry (BMD) Among Osteoporotic Postmenopausal Women
• HDDO-1614 Intervention Trial
• Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids
• Efficacy of Oral Ibandronate in Osteoporosis
• Efficacy of Zoledronic Acid in Osteoporosis
• Effect of VSL#3 on Bone Mineral Density in Postmenopausal Women
• Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis
• Generic Zoledronic Acid Versus Original Zoledronic Acid in Postmenopausal Osteoporotic Women
• Statin Monotherapy for Treatment of Endocrine Metabolic Disease Risk
• Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis
• Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis
• The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury
• Osteoporosis Treatment in Post-menopausal Women
• Denosumab Versus Bisphosphonates (Alendronate) in GIOP
• A Comparison of PF708 and Forteo in Osteoporosis Patients
• The Effects of Seasonal Changes in Osteoporosis Treatment
• A Study To Assess The Quality Of Bone In Patients Taking Oral Ibandronate Versus Placebo
• Simvastatin to Prevent SCI-Induced Bone Loss
• Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis
• Epimedium Prenylflavonoid (EP) Extract for Osteoporosis and Cardiovascular Disease
• The Deferasirox-calcium-vitamin D3 Therapy for Postmenopausal Osteoporosis (PMOP)
• Bone Health in Aging HIV Infected Women
• Study Evaluating Denosumab on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease
• A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis
• Preventing Osteoporosis Using Denosumab
• Exome Sequencing for Atypical Femoral Fractures
• Glucocorticoid-induced Osteoporosis in Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis
• A Comparison Study of PF708 and Forteo in Healthy Subjects
• Secondary Prevention of Osteoporotic Fractures: a Multiple Center Fracture Liaison Service in Greece
• Antiresorptive Effects of a 6-m Treatment Course With Ibandronate Plus Supplementation of Vitamine D and Calcium in Central America
• Denosumab for the Treatment of Osteoporosis in Children: A Pilot Study
• Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study
• A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
• A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis
• PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia
• A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
• Clinical Study of Efficacy and Safety of Chung A Won in Women's Patients With Osteoporosis
• Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)
• Effect of Evogliptin on Bone Metabolism in Human
• Systemic Vitamin D Supplementation in Dental Implants Patients
• PTH And Calcium Responses to Exercise in Older Adults Experiment 2 (PACE Sr. 2)
• Physiologic Interactions Between the Adrenal- and the Parathyroid Glands
• PTH and Vibration in OSteoporosis Study
• Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis
• Denosumab Safety Assessment in Multiple Observational Databases
• Vitamin D Supplementation in Postmenopausal Women With Osteoporosis: Proposal of a Therapeutic Regimen in Practice
• Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation
• Effects of Denosumab Therapy for Japanese
• Novel Biomarkers and Skeletal Outcomes Associated With Subclinical Thyroid Dysfunction
• A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forteo Pen
• Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa
• The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function
• Adherence to Osteoporosis Treatment and Physicians' Perception Regarding Osteoporosis Medication
• Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism
• Traditional Chinese Medicine as Preventive Method for Osteoporosis Induced by Adjuvant Endocrine Therapy
• Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index
• A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers
• Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders
• Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism
• The Forteo Alendronate Comparator Trial
• Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment
• The Effects of Inhaled Glucocorticoids on the Postmenopausal Skeleton
• Effects of Acute Estrogen Therapy on Bone Formation
• Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France
• Effect of Atorvastatin on Bone-vascular Axis
• Prevention of Bone Loss After Acute SCI by Zoledronic Acid
• The Effectiveness of Eldecalcitol in the Bisphosphonate Non-respondered-patients With Osteoporosis
• The Relationship Between the Residual Renal Function and Osteoporosis Treatment
• 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis
• Pharmacokinetics and Tolerability of Minodronic Acid and Food and Age Effects on the Pharmacokinetics
• Observational Study of iv Ibandronate in Women With Postmenopausal Osteoporosis
• Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury (SCI) Previously Treated With Teriparatide
• A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis
• Antidepressants and Bone Mineral Density
• Denosumab and Teriparatide Study (DATA-HD and DATA-EX)
• A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis
• Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients
• Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study
• China HVT Safety, PK, PD
• Study Investigating the Effect of Drugs Used to Treat Osteoporosis on the Progression of Calcific Aortic Stenosis.
• The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab
• Bisphosphonates Effects On Alveolar Bone Among Osteoporotic Women
• A Study of Blosozumab (LY2541546) in Postmenopausal Female Participants
• 36-month Special Drug Use Surveillance on Frequency of Bone Fractures With Sodium Risedronate 75 mg Tablets
• Teriparatide for Fracture Repair in Humans
• Switching From Oral Bisphosphonates to Bazedoxifene to Evaluate Effects on Bone Mineral Density in Postmenopausal Women
• Special Drug Use Surveillance on Long-term Use of Sodium Risedronate Tablets (Benet 75 mg Tablets) (12-month Treatment Survey)
• Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation
• A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets
• Phase 2a Study on Intravenous Infusion of Autologous Osteoblastic Cells in Severe Osteoporosis
• Tocotrienols and Bone Health of Postmenopausal Women
• Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP
• Zoledronic Acid Administration in Acute Spinal Cord Injury
• 12 Month Extension Study of the Effect of Teriparatide on Bone in People With Chronic Spinal Cord Injury (SCI)
• A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis
• Denosumab China Phase III Study
• Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis
• Denosumab Administration After Spinal Cord Injury
• Eldecalcitol for GLucocorticoid Induced OsteopoRosIs Versus Alfacalcidol
• Vitamin D Deficiency in Elderly African American Women in Central Texas
• Safety Study of an Oral Vitamin D Analog in Postmenopausal Women
• Clinical Comparison of Efficacy and Safety of Two Teriparatide Formulations: Osteofortil and Forteo
• A Phase I Study of AK159 in Healthy Postmenopausal Women
• The Effects of Estrogen Replacement Therapy in Postmenopausal Women With Hypercalciuria and Low Bone Mass
• Nasally and sc Administered Teriparatide in Healthy Volunteers
• To Evaluate the Efficacy and the Safety of Monthly Versus Weekly Oral Risedronate With Vitamin D in Compliance, Improvement of Vitamin D and BMD in Korean Postmenopausal Osteoporotic Women
• Ibuprofen Supplementation After Resistance Training and Its Effects on Bone in Older Women
• Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy
• Molecular Mechanism of POP Kidney Yin Deficiency Syndrome From the Interventional Effects of CLCF1
• Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis
• Treatment of Low Bone Density in Cystic Fibrosis.
• Post-menopausal Women Osteoporosis(Phase III)
• Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076)
• Bone Demineralization Lesions in the Injured Marrow: Efficacy and Tolerability of Administration Early and Repeated the Zoledronic Acid. Comparative Study, Prospective, Double-blind Controlled (DBMZol)
• An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women
• Post Marketing Surveillance For General Drug Use To Assess the Safety And Efficacy Profile Of Viviant In Usual Practice
• The Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels
• Weekly vs Daily Teriparatide Therapy in Severe Postmenopausal Osteoporosis
• Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis
• Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption
• Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis
• VERtebral Fracture Treatment Comparisons in Osteoporotic Women
• Fracture (FX) Improvement With Teriparatide: FiX-IT Study
• Multi-centre Clinical Trial on Hormone Replacement Treatment in China
• Treatment of Osteopenia With Melatonin
• Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability
• Efficacy and Safety Study of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis
• Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis
• Vitamin D and Physical Activity for Prevention of Sarcopenia in Osteoporosis
• Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis
• Stem Cell Recruitment in Osteoporosis Therapy
• Zometa Study in Pediatric Acute Lymphoblastic Leukemia
• Eradication of Gut Microbiota
• Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis
• A Study of Odanacatib When Administered to Adolescents and Young Adults Treated With Glucocorticoids (MK-0822-066)
• Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis
• Study to Evaluate Effect of Intranasal Teriparatide on Serum P1NP, a Biomarker of Bone Formation, in Postmenopausal Women With Low Bone Mass
• Transition From Alendronate to Romosozumab (AMG 785)
• Phase III Clinical Trial of DP-R206 and Bonvia In Postmenopausal Women With Osteoporosis
• Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
• Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin of Postmenopausal Women With Low Bone Mass
• Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)
• Clinical Study of AK159 in Healthy Postmenopausal Women
• Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis
• Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis
• Pharmacokinetics of Maxmarvil® in Healthy Postmenopausal Women
• Study of AK156 in Primary Osteoporosis Patients
• Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy
• A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab
• Viviant 20mg Special Investigation (Regulatory Post Marketing Commitment Plan)
• Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis
• Testosterone and Alendronate in Hypogonadal Men
• A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab
• Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women
• Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (MK-0217A-329)
• A Study of Teriparatide in Japanese Osteoporosis Patients
• FES-Rowing Versus Zoledronic Acid to Improve Bone Health in Spinal Cord Injury (SCI)
• Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)
• Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density
• IGF-1 and Bone Loss in Women With Anorexia Nervosa
• Wellnara Post-marketing Surveillance in Japan
• Julina Post-marketing Surveillance for Postmenopausal Osteoporosis in Japan
• Nitrates and Bone Turnover; Nitrates and Bone Turnover Bisphosphonate Sub-Study
• Julina Post-marketing Surveillance for Climacteric Symptoms in Japan
• BONVIVA(Ibandronate) PMS(Post-marketing Surveillance )
• Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients
• BONVIVA(Ibandronate) Injection PMS(Post-marketing Surveillance)
• Teriparatide Treatment in Patients With Inherited Osteoporosis
• A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264)
• Efficacy Of Clodronate 200 Mg/4 Ml I.M. Solution With 1% Lidocaine Every Other Week Vs Clodronate 100 Mg/3,3ml I.M. Solution With 1% Lidocaine Once-Week In A 1-Year Treatment Period Of Women With Postmenopausal Osteoporosis
• Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women
• One Week Comparison Study of PTH and PTHrP Infusions
• Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women
• Early Effects of Parathyroid Hormone (PTH) on the Proximal Femur
• Effects of Denosumab on the Pharmacokinetics of Etanercept
• Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of Action
• A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis
• A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis
• Efficacy of Monthly Ibandronate in Women With RA and Reduced Bone Mineral Density Receiving Long-term Steroids
• Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty
• A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women
• Effect of Stopping Risedronate After Long Term Treatment on Bone Turnover
• Vitamin K as Additive Treatment in Osteoporosis
• Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)
• Effect of Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in Chronic Spinal Cord Injury
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women
• Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate
• The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam
• 1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids
• Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window?
• Zoledronic Acid in MS-patients With Osteoporosis
• Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women
• Teriparatide (PTH) and Bone Strength in Postmenopausal Women
• Effects of Teriparatide (PTH) on Bone in Men and Women With Osteoporosis
• µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis
• A Study of LY2541546 in Women With Low Bone Mineral Density
• Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI
• Pilot Study of Fosamax in Spinal Cord Injury
• A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis
• A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053)
• Trial of Lithium Carbonate for Treatment of Osteoporosis-pseudoglioma Syndrome
• Treatment With Alendronate in Patients With Ankylosing Spondylitis (AS)
• Study of FORTEO Use in Subjects in the Community Setting
• Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)
• Safety and Tolerability of Odanacatib (0822-059)
• FOSAMAX PLUS and FOSAMAX PLUS D Re-examination Study (0217A-267)
• Angeliq Regulatory Post Marketing Surveillance
• A Cross-sectional Study to Investigate the Effect of Topiramate on Bone and Mineral Metabolism in Female Participants With Epilepsy
• Safety, Tolerability and Efficacy of MK0773 in Healthy Postmenopausal Women (0773-003)
• A Study for the Transdermal Application of Teriparatide
• MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)
• Intra-venous Zoledronic Acid Once Yearly
• Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis
• A Study to Evaluate Food Effect on ONO-5920/YM529 Intermittent Formulation
• A Dose-Ranging Study of MK-5442 in Postmenopausal Women With Osteoporosis (MK-5442-001)
• A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women
• Switch From Tenofovir to Raltegravir for Low Bone Mineral Density
• A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates
• Drug Holidays in the Treatment With Alendronate in Postmenopausal Women With Osteoporosis
• Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women
• Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis
• Alendronate in Juvenile Osteoporosis
• Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy
• Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women
• A Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on Bone Mineral Density (BMD) in Postmenopausal Osteoporosis (PMO) Patients Between the Ages of 50 and 65 Years
• Impact of Vitamin D Supplementation on Lactation Associated Bone Loss
• Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density
• A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab
• A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab
• A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture
• A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (MK-0822-042)
• Effects of Continuous Combined Hormone Replacement Therapy and Clodronate on Bone Mineral Density (BMD) in Osteoporotic Women
• Antiepileptic Drugs and Osteoporotic Prevention Trial
• A Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822) in Healthy Volunteers
• A Study to Assess the Effects of a Light Breakfast on the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822)
• A Study of Prevention and Treatment of Postmenopausal Osteoporosis in Chinese Women
• Comparison Study of PTHrP and PTH to Treat Osteoporosis
• A Study to Assess the Bioequivalence of Different Formulations of Risedronate in Healthy Male and Female Subjects
• Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis
• Analysis of Iliac Crest Biopsies From Patients Receiving Risedronate
• Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI)
• Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients
• Use of Oral Bisphosphonates in the Treatment of Osteoporosis of Non-walking Children With Cerebral Palsy
• Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis
• Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone
• A Study of the Bioequivalence of 70 mg Alendronate and 70 mg Alendronate in Combination With 2800 IU Vitamin D
• A Study of the Bioequivalence of 70-mg Alendronate and 70-mg Alendronate in Combination With 5600 IU Vitamin D (MK0217A-253)
• An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids
• Zoledronate for Osteopenia in Pediatric Crohn's
• Efficacy And Security Of Annual And Biennial Zoledronic Acid For Osteoporosis Treatment In An HIV-Infected Patients' Cohort
• ONO-5920/YM529 Confirmatory Study in Involutional Osteoporosis Patients
• Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation
• Study Evaluating Changes In Mammographic Breast Density
• Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis
• A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED)
• Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002)
• A Study of Arzoxifene to Treat Korean Women With Osteoporosis
• Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption?
• Back Pain in Patients With Severe Osteoporosis
• The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa
• Growth Hormone Therapy and Bone Quality in Pediatric Osteoporosis
• Study Evaluating Changes In Bone Mineral Density (BMD), And Safety Of Rhbmp-2/CPM In Subjects With Decreased BMD
• Feasibility of Doctors' Rooms-based Infusion of Zoledronic Acid
• Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263)
• Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)
• Osteoporosis and Dental Implant
• The Effect of Protein on Calcium Absorption and Gastric Acid Production
• 3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs
• Phase 2 Safety and Efficacy Study of a Vitamin D Compound (DP001) in Postmenopausal Women With Low Bone Mineral Density
• The Effect of PTH(1-84) or Alendronate on Reduction of Back Pain in Postmenopausal Women With an Osteoporosis Related Vertebral Fracture(s) (FP-005-IM)
• Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects
• Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women
• A Study for Teriparatide in Severe Osteoporosis
• Study of PH3 for the Prevention of Osteoporosis in Postmenopausal Women
• A Study to Test the Effect of MK0217A on Vitamin D Inadequacy in Postmenopausal Women With Osteoporosis (0217A-262)
• PTH & Ibandronate Combination Study (PICS)
• Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis
• Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of PTH134 at Increasing Doses in Healthy Postmenopausal Subjects
• Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women
• The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation
• Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis
• Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis
• Cyclic Versus Daily Teriparatide on Bone Mass
• Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus
• Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects
• Study Of The Efficacy And Security Of Ibandronate For Osteoporosis Treatment In A HIV-Infected Patients Cohort
• Prevention of Post Operative Bone Loss in Children
• To Estimate Relative Bioavailability of 5 Formulations of Ronacaleret Given to Healthy Postmenopausal Females
• 4-Week Study to Assess the Effect of Alendronate and Vitamin D3 Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women (0217A-230)
• A Study to Determine the Satisfaction With Actonel in Postmenopausal Women With Osteoporosis
• Green Tea and Tai Chi for Bone Health
• Study to Evaluate Effect of Intranasal Teriparatide on Bone Mineral Density in Postmenopausal Women With Low BMD
• A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women
• Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022)
• Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis
• Impact of Vertebral Fracture Knowledge on Persistence in Subjects Taking Glucocorticoid Therapy
• STEP: Study of Imaging Techniques (ImaTx and DXA) in Postmenopausal Women With OstEoporosis Using Preotact (FP-008-ES)
• Does Omeprazole Decrease Intestinal Calcium Absorption?
• Does Treatment of Hypovitaminosis D Increase Calcium Absorption?
• One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study
• Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy
• Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose
• Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO
• Bone Microarchitecture in Osteopenic Postmenopausal Women
• Glucocorticoids Promote Osteoclast Survival
• Zoledronic Acid for Osteoporosis in the Elderly
• A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide
• A Study of SB751689 in Japanese Postmenopausal Women
• A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment
• Satisfaction and Compliance of Risedronate in PMO
• POWER Point of Care Effect on Satisfaction of Treatment
• The Effect of Vitamin K2 on Bone Turnover
• BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis
• BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.
• SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.
• A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP)
• ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.
• A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.
• ROSPA - Record on Satisfaction of Patients With Actonel 35 mg Once a Week
• PTH Comparison in Post Menopausal Women
• A Study of the Treatment of Postmenopausal Women With Osteoporosis
• Comparison Medications in the Treatment of Postmenopausal Women With Osteoporosis
• Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis
• A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis
• A Study to Estimate the Effect of Formulation on the Relative Absorption of SB-751689 Administered to Healthy Women
• Changes in Bone Mineral Density and Fracture Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer
• Efficacy & Safety of ViaDerm-hPTH(1-34) Compared to Forteo SC in Postmenopausal Women With Osteoporosis
• Proof of Concept (Bone Resorption/Bone Mineral Density) Study (0429-005)
• Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis
• Long Term Effects of Raloxifene Treatment on Bone Quality
• Controlled Study of ONO-5334 in Postmenopausal Women With Osteopenia or Osteoporosis
• Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo
• Study of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis
• A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women
• A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)
• A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D
• Frequency of Zoledronic Acid to Prevent Further Bone Loss in Osteoporotic Patients Requiring Androgen Deprivation Therapy for Prostate Cancer
• Trial to Evaluate Tibolone in the Treatment of Osteoporosis (P06468)
• Denosumab Adherence Preference Satisfaction Study
• PROPOSE Quality - PReOtact in Postmenopausal OStEoporosis - Quality of Life Study (FP-004-DE)
• A Study To Evaluate The Effects Of Repeat Dosing Of Esomeprazole On The Pharmacokinetics Of SB-751689 In Healthy People
• Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis
• Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women
• Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced Osteoporosis
• A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
• Safety and Efficacy of OSTEOFORM (rhPTH [1-34]) in Increasing Bone Mineral Density in Osteoporosis
• A Study To Investigate The Metabolism And Excretion Of 14C SB-751689 Given To Healthy Males And Postmenopausal Women
• Androgen Therapy for Breast Cancer Patients With Aromatase Inhibitor Induced Side-Effects
• BONDIR Study: A Study of Intravenous Bonviva (Ibandronate) After Recent Vertebral Osteoporotic Fracture in Patients With Osteoporosis.
• A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.
• High Dosage Vitamin D and Osteoporosis
• Dose Ranging Study - Macroflux Parathyroid Hormone (PTH) in Postmenopausal Women With Osteoporosis
• Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass
• Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy
• Study Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal Women
• A Research Study to Evaluate the Safety and Effectiveness of MK0217 to Prevent and Treat Bone Loss (0217-193)(COMPLETED)
• Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis (FP-006-IM)
• A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.
• Evaluation Of SB-751689 Administered At Supratherapeutic Dose Levels In Healthy Adult Subjects.
• Osteoporosis Prevention With Low Dose Alendronate
• The Change of Bone Markers After Low Dose Alendronate in Postmenopausal Women With Bone Loss
• Risedronate Sodium in Post Menopausal Osteoporosis
• Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis
• The Effects of Ibandronate or Teriparatide Therapy on Bone Histology and Biochemical Indices in Patients on Hemodialysis With Low Bone Mineral Density
• Determination of Adipocyte Parameters in Iliac Crest Biopsies From Post Menopausal Women
• Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis
• Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis
• Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer
• Phase 3 Clinical Trial of Teriparatide in Japan
• Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density
• Secondary Prevention of Osteoporosis
• A Study for Patients With Osteoporosis
• Study To Determine The Effects Of Doses Of Relacatib On The Metabolism Of Acetaminophen, Ibuprofen And Atorvastatin
• Pharmacokinetics and Pharmacodynamics Study of Oral Salmon Calcitonin in Healthy Postmenopausal Women
• A Dose-response Study With Strontium Malonate in Postmenopausal Women
• Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis
• Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis
• Risedronate in the Prevention of Osteoporosis in Postmenopausal Women
• Upper GI Handling of Branded vs. Generic Alendronate
• FLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051)
• A Study to Compare the Efficacy of Alendronate With and Without Calcium or Calcium Alone In the Treatment of Osteoporosis in Postmenopausal Women (0217-088)(COMPLETED)
• The Effect Of Oral Ibandronate In Male Osteoporosis
• Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal Women
• Fosamax for Childhood Cancer Survivors
• A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)
• A Study Of SB-751689, Atorvastatin, Ketoconazole, And Rosuvastatin In Health Postmenopausal Women.
• Study Evaluating the Safety and Efficacy of Bazedoxifene in Postmenopausal Asian Women
• Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis
• Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.
• Study of Transitioning From Alendronate to Denosumab
• 7 Day Continuous Parathyroid Hormone IV Infusion
• A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.
• Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole
• HRT Versus Etidronate for Osteoporosis and Fractures in Asthmatics Receiving Glucocorticoids.
• The Efficacy of Risedronate in Prevention of Bone Loss in Patients Receiving High Dose Corticosteroid Treatment
• Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid Therapy
• A Pilot Methodology Study To Evaluate Changes In Bone Quality Parameters Following Therapy With Forteo
• Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)
• Intervenous (IV) Zoledronic Acid After Forteo in Postmenopausal Women
• Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women
• Effect of Calcium and Vitamin D on Bone Loss From the Hip
• The Effects of Potassium Citrate on Bone Metabolism
• Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial
• Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women
• Risedronate in Postmenopausal Women With Low Bone Density
• The Effects of Therapy With Teriparatide on Vascular Compliance and Osteoprotegerin/RANKL
• Magnesium Supplementation to Prevent Bone Loss
• The Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.
• Risedronate in Osteopenic Postmenopausal Women
• Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis
• Determinants of Vitamin K Metabolism
• Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
• A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.
• Effects of Hesperidin on Bone Mineral Density and Bone Metabolism of Postmenopausal Women
• Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
• Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthly Ibandronate And Once Weekly Alendronate
• Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS
• Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant
• The Effect of Norgestimate/Ethinyl Estradiol on Bone Density in Pediatric Subjects With Anorexia Nervosa
• 3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women
• A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects
• Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries
• Prostate Adenocarcinoma TransCutaneous Hormones
• A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)
• Use of Bisphosphonates in the Treatment of Osteopathy After Liver Transplantation
• Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma
• Effects of Phytoestrogen-rich Diets on Bone Turnover in Postmenopausal Women
• Effects of Tibolone Treatment on the Endometrium
• A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density
• Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa
• Alendronate Osteoporosis Study
• Impact of Oral Ibandronate 150 mg Monthly on Structural Properties of Bone in Postmenopausal Osteoporosis (SPIMOS-3D)
• IMPACT Study (Improving Measurements of Persistence on "ACtonel" Treatment)
• Can Alendronate Suppress Calcification and Improve Bone Density in Chronic Peritoneal Dialysis Patients?
• Safety and Efficacy of Alendronate (Fosamax) in Children With Osteoporosis
• Evaluation of the Effects of Teriparatide on Skeleton Images in Postmenopausal Women With Osteoporosis
• The Nitrate and Bone Study: Effects of Nitrates on Osteoporosis
• Danish Osteoporosis Prevention Study
• A Study of Monthly Risedronate for Osteoporosis
• Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women
• Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial
• Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis.
• Cancer and Osteoporosis Research With Alendronate and Lupron (C.O.R.A.L )
• 3-Week Parathyroid Hormone-related Protein (PTHrP) Dose Escalation Study in Post-Menopausal Women
• Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use
• Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan
• Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan
• Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan
• Network Osteoporosis Study
• Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women
• Vitamin D Administration in the Nursing Home
• Safety and Efficacy Study of Bugusan (BGS)to Treat Osteoporosis.
• Bone Effects of Teriparatide Following Alendronate
• Clinical Trial of Teriparatide in Japan
• Compliance and Acceptance of Teriparatide Injection in Severely Osteoporotic Patients
• 2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis
• Teriparatide Use in Hip Replaced Subjects
• A Severity-Adapted Clinical Trial of Diminished Bone Mineral Density in Acute Lymphoblastic Leukemia Survivors
• Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification
• Testosterone Effects on Bone and Frailty
• Prevention of Osteoporosis in Men With Prostate Cancer on Androgen Deprivation Therapy (POP Study)
• "PTHrP(1-36) IV Dose Escalation Study"
• Calcium Supplementation in Postmenopausal Women
• Open Label Extension Study of PREOS
• Open Label Extension
• A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
• TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
• The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis
• Efficacy and Safety of AAE581 in Postmenopausal Women With Osteopenia/Osteoporosis.
• Influence of Alfacalcidol on Falls in Osteopenic/Osteoporotic Postmenopausal Women (ALFA Study)
• Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women
• Randomized, Open, Parallel, Active Controlled Study on Fracture Prevention in Antiosteoporosis Treatment (OF Study)
• Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss
• Bisphosphonate Therapy for Osteogenesis Imperfecta
• Study of Alendronate to Prevent and Treat Osteoporosis in Cystic Fibrosis Patients
• Pseudodrynaria Coronana (Wall) Ching
• Davallia Divaricata BL: The Use of Traditional Chinese Native Medicine for Osteoporosis
• Risedronate for the Prevention of Osteoporosis in People With Spinal Cord Injury.
• A Study To Assess the Quality and Strength of Bone in Women Participants With Osteoporosis Taking Oral Ibandronate Versus Placebo
• Texture Analysis for Postmenopausal Osteoporosis
• Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)
• A New Active Vitamin D, ED-71 for Osteoporosis
• Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose Evaluation
• Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)
• Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.
• Risedronate for the Treatment of Osteoporosis for People With Spinal Cord Injury
• Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients
• OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women
• Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy
• Efficacy of Alendronate Versus Placebo in the Treatment of HIV-associated Osteoporosis (ANRS120)
• Atorvastatin (Lipitor) to Prevent Bone Pain
• The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)
• The Effect of Zoledronic Acid on Bone Density in Liver Transplant Patients
• Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density
• A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004)
• Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer
• Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial.
• Bisphosphonate Therapy for HIV-Infected Adults With Decreased Bone Mineral Density
• Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis
• Safety and Efficacy of AAE581 in Postmenopausal Women With Osteoporosis
• A Study of the Clinical Safety, Tolerability, and Efficacy of Zoledronic Acid Compared to an Oral Bisphosphonate
• Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men
• Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid
• A Study of MK0217A and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)
• A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)
• Study of Investigational Drug in Osteoporosis (MK-0217-908)
• A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907)
• A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)
• A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)
• Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis
• A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis
• Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer
• Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women
• A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva
• Effects of Teriparatide in Postmenopausal Women With Osteoporosis
• Hormone Replacement Therapy in Relieving Menopausal Symptoms in Postmenopausal Women With Previous Stage I or Stage II Breast Cancer
• An Investigation Into the Short Term Effect of APOMINE in Patients With Osteoporosis or Low Bone Mass
• Adding Phosphorus to Osteoporosis Drug Treatment
• Once Weekly Parathyroid Hormone for Osteoporosis
• Vitamin K and Bone Turnover in Postmenopausal Women
• Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
• Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer
• Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis
• Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
• HORIZON-PFT: Pivotal Fracture Trial
• Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer
• Prevention of Osteoporosis in Men With Prostate Cancer
• DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
• MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
• Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture
• Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis
• Nitroglycerin Ointment for Preventing Bone Loss in Postmenopausal Women
• Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer
• EVA: Evista Alendronate Comparison
• Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis
• Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer
• Encouraging Calcium Absorption and Bone Formation During Early Puberty
• Prevention of Steroid-Induced Osteoporosis in Children
• Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer
• PTHrP and Osteoporosis
• Combination Osteogenic Therapy in Established Osteoporosis
• Hormone Replacement Therapy to Treat Turner Syndrome
• Effects of Black Cohosh on Menopausal Hot Flashes
• Dietary Phytoestrogens and Bone Metabolism
• Phase II Study of Alendronate Sodium in Children With High-Turnover Idiopathic Juvenile Osteoporosis
• Randomized Study of Growth Hormone on Bone Mineral Density in Patients With Adult Onset Growth Hormone Deficiency
• The Relationship Between Vitamin D, Fingernail Thickness and Bone Density
• Bone Loss in Premenopausal Women With Depression
• Parathyroid Hormone (PTH) With Alendronate for Osteoporosis
• PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis
• Can Parathyroid Hormone Injections Reverse Glucocorticoid-induced Osteoporosis
• Phase III Randomized Study of the Effect of Postmenopausal Estrogen Replacement Therapy on Alveolar Bone Loss
• Randomized Study of Alendronate in Adult Patients With Cystic Fibrosis Related Osteoporosis
• Randomized Study of Human Parathyroid Hormone in Middle-Aged Men With Idiopathic Osteoporosis
• Hormone Replacement in Young Women With Premature Ovarian Failure
• Treatment of Childhood Osteoporosis With Alendronate (Fosamax)
• Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)
• CVD Risk and Health in Postmenopausal Phytoestrogen Users
• Women's Health Initiative (WHI)
• Postmenopausal Estrogen/Progestin Interventions (PEPI)
• Low-Dose Hormone Replacement Therapy and Alendronate for Osteoporosis
• Effects of Parathyroid Hormone in Men With Osteoporosis
• Treatment of Calcium Deficiency in Young Women
• Osteoporosis Prevention After Heart Transplant
• Calcium and Bone Mass in Young Females
• Alendronate and/or Parathyroid Hormone for Osteoporosis
• Bone Estrogen Strength Training